{"page":{"totalFilteredElements":16},"studies":[{"active":true,"description":"A phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator&#8217;s choice monotherapy treatment in previously treated patients with incurable, metastatic/recurrent head and neck squamous cell carcinoma","eudractNumber":"2023-510322-32","id":9816,"indications":[{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno3","name":"Kopf-Hals-Malignome"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-04-02T09:52:31+02:00","shortTitle":"MERUS MCLA-158-CL02","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_3","name":"Drittlinie"},{"id":"tl_4","name":"> Drittlinie"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"<div>A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2</div><div>Inhibitor ABBV-453 given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple Myeloma</div><div><br /></div>","eudractNumber":"2024-517140-65","id":11953,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"BCL (B-cell lymphoma)","id":"mt_202"},{"name":"BCL-2","id":"mt_74"},{"name":"Translokation","id":"mt_244"},{"name":"t(11;14)","id":"mt_78"}],"nctNumber":"NCT06953960","phase":{"id":"ph_5","name":"Phase I/II"},"recruitmentStart":"2026-04-30T15:02:51+02:00","shortTitle":"Multiple Myeloma: Evaluate the Safety and Efficacy of ABBV-453 in Monotherapy or in Combination with Antimyeloma Regimens","therapeutical":true,"therapyLines":[{"id":"tl_4","name":"> Drittlinie"}]},{"active":true,"description":"Prospektives, akademisches, translationales Forschungs-Netzwerk zur Optimierung der onkologischen Gesundheitsversorgung Qualit&#228;t in der adjuvanten und der fortgeschrittenen/metastasierten Situation: Gesundheitsforschung, Pharmakogenomik, Biomarker, Gesundheits&#246;konomie PRAEGNANT Brustkrebs: Fortgeschritten/ Metastasierend<div><b>VERSORGUNGSFORSCHUNGSSTUDIE</b><br /></div>","eudractNumber":"2014-000854-12","id":4161,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT02338167","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2014-08-26T09:40:07+02:00","shortTitle":"PRAEGNANT Mammakarzinom","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"},{"id":"tl_4","name":"> Drittlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"A non-interventional study of selinexor (Nexpovio) in combination with bortezomib and dexamethasone (SVd) in patients with relapsed or refractory multiple myeloma (R/RMM) - SEATTLE -","eudractNumber":null,"id":11163,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-02-01T14:17:05+01:00","shortTitle":"SEATTLE","therapeutical":false,"therapyLines":[{"id":"tl_4","name":"> Drittlinie"}]},{"active":true,"description":"<p class=\"MsoNormal\">A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (SUCCESSOR-1)</p><p class=\"MsoNormal\"><b>CA057-001</b></p>","eudractNumber":"2023-509859-13","id":10285,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05519085","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-03-13T15:17:15+01:00","shortTitle":"SUCCESSOR-1","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_3","name":"Drittlinie"},{"id":"tl_4","name":"> Drittlinie"}]},{"active":true,"description":"<div>A Phase 3 Randomized Study Comparing JNJ-79635322 and&#160;</div><div>an anti-BCMA AxCD3 Bispecific Antibody in Participants with Relapsed or Refractory Multiple Myeloma who Have Received at least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody</div>","eudractNumber":"2025-522007-18","id":11964,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT07258511","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-06-23T12:17:39+02:00","shortTitle":"Trilogy-4","therapeutical":true,"therapyLines":[{"id":"tl_4","name":"> Drittlinie"}]}]}